–Strong anti-tumor activity, favorable oral bioavailability and drug-like properties demonstrated in preclinical models –
–Data support ongoing IND-enabling studies for planned clinical evaluation in KRASG12V-driven solid tumors –
April 08, 2024 -- Quanta Therapeutics, a privately-held biopharmaceutical company leading innovative development of direct, oral therapeutics for RAS-driven cancers, announced the presentation of QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ mu